Table 1 Characteristics of eligible studies
| Study | Year | Type | Population | Platinum-based regimen | Nonplatinum regimen | Outcomes |
|---|---|---|---|---|---|---|
| GEICAM/2006–03 [19] | 2012 | Randomized phase 2 trial | TNBC | EC × 4 ➔ DCb × 4 cycles | EC × 4 ➔ D × 4 cycles | pCR: EC-D 35% EC-DCb 45% (p = 0.606) |
| Ando [20] | 2014 | Randomized phase 2 trial | TNBC | CP q wk. x 12 ➔ CEF × 4 cycles | P q wk. × 12 ➔ CEF × 4 cycles | pCR: CP-CEF 31.8% P-CEF 17.6% (p = 0.01) |
| WSG-ADAPT-TN [21] | 2017 | Randomized phase 2 trial | TNBC | Nab-P/ Cb × 4 | Nab-P/ Gem × 4 | pCR Nab-P-Cb 45.9% Nab-P-Gem 28.7% p = 0.002 |
| BrighT Ness [22] | 2018 | Randomized phase 3 trial | TNBC | Arm 1: PCb + Veliparib × 4 cycles Arm 2: PCb + Veliparib placebo × 4 cycles | Arm 3: Paclitaxel + Carboplatin placebo + Veliparib placebo × 4 cycles | pCR Arm 1 53% Arm 2 58% Arm 3 31% |
| CALGB 40603 [11] | 2015 | Randomized phase 2 trial | TNBC | Arm 3: P x 12w + Cb × 4 ➔ ddAC × 4 Arm 4: P × 12w + Cb × 4 + Bev × 9 ➔ ddAC × 4 | Arm 1: P x 12w ➔ ddAC × 4 Arm 2: P × 12w + Bev q2w x 9w ➔ ddAC × 4 | pCR (+) Cb 60% (−) Cb 46% (+) Bev 59% (−) Bev 48% |
| TNT Trial [23] | 2018 | Randomized phase 3 trial | TNBC | Cb | D | pCR Cb 6.7% D 3.3% |
| Gepar Sixto [4] | 2014 | Randomized phase 2 trial | TNBC | Cb + PDB x 18w or Cb + PDH x 18w | PDB x 18w or PDH x 18w | pCR (+) Cb 43.7% (−) Cb 36.9% |
| Zhang [24] | 2016 | Randomized phase 2 trial | TNBC | PCb | EP | pCR PCb 38.6% EP 14.0% |
| CBCSG006 [17] | 2015 | Randomized phase 3 trial | Metastatic TNBC | Gemcitabine/ Cisplatin × 8 cycles | Gemcitabine / Paclitaxel × 8 cycles | OS Gem/Cis × 8 59% Gem/P × 8 58% p = 0.611 |
| Carey [16] | 2012 | Randomized phase 2 trial | Metastatic TNBC | Cet/ Cb | Cet | PFS: Cet + Cb 77% Cb 97% OS: Cet + Cb 83% Cb 83% |
| Fan [25] | 2012 | Randomized phase 2 trial | Metastatic TNBC | DP × 6 cycles | DX × 6 cycles | PFS: TP 25% TX 10% p < 0.001 OS TP 28% TX 10% p = 0.02 |